- Trial phase
- Preclinical
- Time to market
- Preclinical stage with no disclosed IND timeline. If development proceeds, clinical trials would likely take several years, meaning potential approval is likely 5+ years away, if at all.
- Why 2/10
- PN-8047 is a preclinical asset with no scheduled hard catalyst (no IND, no clinical trial, no PDUFA date) within the next 12 months. It is one of several early-stage programs at a company whose value is driven by two approved products (ICOTYDE, MIMRYLO) and the more advanced PN-881 program. ImpactScore is 2: preclinical/minor program with nothing scheduled.
PN-8047 has no near-term catalysts. The next meaningful pipeline catalyst for Protagonist is the Phase 2b initiation of PN-881 in early Q1 2027. Watch for any preclinical data disclosures or IND filing announcements for PN-8047 in future earnings calls or scientific conferences, but this program is unlikely to move the stock in the next 12 months.
Price Chart
Executive Summary
PN-8047 is a preclinical-stage, wholly-owned oral hepcidin mimetic being developed by Protagonist Therapeutics (PTGX). It was first disclosed in the company's Q4 2025 earnings release in February 2026 as part of an expanded preclinical pipeline. PN-8047 is an oral follow-on to MIMRYLO (rusfertide), Protagonist's injectable hepcidin mimetic that received FDA approval in August 2026 for polycythemia vera. As a preclinical asset with no disclosed IND timeline, no clinical data, and no near-term catalysts, PN-8047 is a very early exploratory program. Protagonist's current market value is driven primarily by its two approved products (ICOTYDE for psoriasis and MIMRYLO for polycythemia vera) and its more advanced pipeline candidate PN-881 (Phase 1 completed, Phase 2b planned for early Q1 2027).
How It Works
PN-8047 is an oral hepcidin mimetic. Hepcidin is a hormone that controls how the body absorbs and uses iron. By mimicking hepcidin, the drug aims to reduce excess iron in the blood. This is an oral version of the same mechanism as Protagonist's already-approved injectable drug MIMRYLO (rusfertide), which treats polycythemia vera, a condition where the body makes too many red blood cells.
Trial Status
PN-8047 is in preclinical development. It was first disclosed in Protagonist's Q4 2025 earnings release in February 2026. No IND has been filed, no clinical trials have been initiated, and no clinical data have been reported. The program is part of Protagonist's wholly-owned preclinical pipeline alongside PN-477 (triple GLP-GIP-GCG agonist) and PN-458 (dual GLP-1/GIP receptor agonist).
The Two-Sided Case
Upcoming Catalysts
- No near-term catalysts for PN-8047 specifically. The next pipeline catalyst for Protagonist is PN-881 Phase 2b initiation expected in early Q1 2027.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Protagonist Therapeutics, Inc 8-K PTGX ·Originating report